The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study

BackgroundPD-1/L1 inhibitor-based immunotherapy is currently under investigation in biliary tract cancer (BTC). Apatinib combined with camrelizumab has achieved promising results in various tumor types. The aim of this study was to assess the safety and efficacy of apatinib plus camrelizumab for adv...

Full description

Bibliographic Details
Main Authors: Dongxu Wang, Xu Yang, Junyu Long, Jianzhen Lin, Jinzhu Mao, Fucun Xie, Yunchao Wang, Yanyu Wang, Ziyu Xun, Yi Bai, Xiaobo Yang, Mei Guan, Jie Pan, Samuel Seery, Xinting Sang, Haitao Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
apatinib
camrelizumab (SHR-1210)
advanced biliary tract cancer
combination therapy
PD-1/L1 blockade
target therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.646979/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.646979/full

Similar Items